EP3239138A1 — Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
Assigned to Sandoz AG · Expires 2017-11-01 · 9y expired
What this patent protects
The present invention relates to pitolisant hydrogen fumarate and a process for its preparation. The invention also relates to pharmaceutical compositions comprising pitolisant hydrogen fumarate and to the use of pitolisant hydrogen fumarate and of said pharmaceutical composition…
USPTO Abstract
The present invention relates to pitolisant hydrogen fumarate and a process for its preparation. The invention also relates to pharmaceutical compositions comprising pitolisant hydrogen fumarate and to the use of pitolisant hydrogen fumarate and of said pharmaceutical compositions as a medicament, in particular for the treatment of narcolepsy with or without cataplexy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.